Veeva Systems (NYSE:VEEV) SVP Jonathan Faddis Sells 5,198 Shares of Company Stock

Veeva Systems Inc. (NYSE:VEEV) SVP Jonathan Faddis sold 5,198 shares of Veeva Systems stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $299.72, for a total value of $1,557,944.56. Following the sale, the senior vice president directly owned 4,130 shares in the company, valued at approximately $1,237,843.60. The trade was a 55.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Veeva Systems Stock Performance

Shares of VEEV traded down $2.13 during mid-day trading on Friday, reaching $310.90. The company had a trading volume of 1,730,063 shares, compared to its average volume of 1,686,745. Veeva Systems Inc. has a 52 week low of $148.05 and a 52 week high of $319.95. The company has a market capitalization of $50.34 billion, a price-to-earnings ratio of 51.14, a price-to-earnings-growth ratio of 1.34 and a beta of 0.93. The firm has a 50-day moving average price of $269.81 and a 200 day moving average price of $207.95.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings data on Wednesday, August 26th. The technology company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.23 by $0.12. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%. The company had revenue of $927.96 million during the quarter, compared to the consensus estimate of $905.38 million. During the same period last year, the company earned $1.99 EPS. Veeva Systems’s revenue for the quarter was up 17.6% on a year-over-year basis. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. As a group, research analysts forecast that Veeva Systems Inc. will post 6.70 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Veeva Systems

A number of hedge funds and other institutional investors have recently made changes to their positions in VEEV. KRS Capital Management LLC bought a new position in Veeva Systems during the 3rd quarter worth about $287,000. Avail Investment Partners LLC purchased a new position in Veeva Systems during the 3rd quarter valued at about $290,000. Guardian Asset Advisors LLC purchased a new position in Veeva Systems during the 3rd quarter valued at about $210,000. Hengehold Capital Management LLC bought a new stake in shares of Veeva Systems in the 3rd quarter valued at about $288,000. Finally, Aspiriant LLC bought a new stake in shares of Veeva Systems in the 3rd quarter valued at about $256,000. Institutional investors own 88.20% of the company’s stock.

Veeva Systems News Summary

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: IQVIA selected Veeva’s clinical software as an enterprise standard. IQVIA will use Veeva Clinical Trial Management System, eTMF, Study Startup, and Site Connect across its global research operations. The agreement expands Veeva’s role in IQVIA’s clinical workflow, strengthens its position with contract research organizations and biopharma customers, and could support recurring revenue growth. Veeva Systems Becomes Default Clinical Software Across a Major Research Partner
• Positive Sentiment: Technical momentum and institutional interest have accelerated. Reports said Veeva broke above a buy point as “big money” added exposure to the company’s AI-related software opportunity. Shares subsequently reached a fresh 52-week high and posted sizable single-session gains, attracting additional momentum-oriented investors. Veeva Stock Breaks Out As Big Money Grabs Exposure To The AI Software Play
• Positive Sentiment: Analyst coverage remains favorable. Oppenheimer maintained a $325 price target, while the average Wall Street recommendation remains positive. These views reinforce the market’s expectation that Veeva can continue expanding despite a potential moderation in research-and-development growth. Oppenheimer Keeps $325 Target for Veeva Systems Stock
• Neutral Sentiment: More than 175 emerging biotechs are reportedly using Veeva Basics, indicating continued adoption of the company’s broader cloud software platform. However, the immediate financial impact was not quantified. Veeva’s Clinical Technology Moat and IQVIA Deal
• Negative Sentiment: Senior Vice President Jonathan Faddis sold 5,198 shares for approximately $1.56 million, reducing his direct ownership by 55.7%. The transaction occurred under a pre-arranged Rule 10b5-1 plan, which limits its significance as a discretionary bearish signal, but insider selling can still temper enthusiasm after a strong rally. SEC Insider Transaction Filing

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on VEEV shares. Wall Street Zen raised shares of Veeva Systems from a “hold” rating to a “buy” rating in a report on Saturday, October 10th. Guggenheim upped their price target on shares of Veeva Systems from $276.00 to $310.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. Canaccord Genuity Group increased their price objective on shares of Veeva Systems from $220.00 to $260.00 and gave the company a “hold” rating in a research report on Thursday, August 27th. Oppenheimer reissued an “outperform” rating and issued a $325.00 price objective on shares of Veeva Systems in a research note on Thursday. Finally, Mizuho lifted their price objective on shares of Veeva Systems from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, August 27th. Nineteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Veeva Systems currently has a consensus rating of “Moderate Buy” and a consensus price target of $285.92.

Veeva Systems Company Profile

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company’s product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.